Gan & Lee Pharmaceuticals Co., Ltd. Class ASSE: 603087

"Gan & Lee Pharmaceuticals"Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GZC8072 Tablets

Sep 8, 2026 · Issued by Gan & Lee Pharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GZC8072 Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Gan & Lee Pharmaceuticals Co., Ltd. Class A

"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trial for the New Indication of GZC8072 TabletSep 4
"Gan & Lee Pharmaceuticals."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the SharesAug 27
"Gan & Lee Pharmaceuticals."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 26
"Gan & Lee Pharmaceuticals."Announcement on Obtaining Notice of Approval for Drug Clinical TrialsAug 25

All Gan & Lee Pharmaceuticals Co., Ltd. Class A news releases